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Abstract
Combined atrial septal defect and pulmonic or aortic stenosis are relatively
uncommon conditions in adult patients, with few reported cases of percutaneous
treatment. We present two patients with secundum type atrial septal defect
and concomitant pulmonic or aortic stenosis and their treatment by
transcatheter techniques.
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Introduction
Secundum type atrial septal defect (ASD) combined with pulmonic or
aortic stenosis is a relatively uncommon condition in adult patients.
Percutaneous closure of ASD in indicated patients is a legitimate alternative
to surgical treatment. Percutaneous balloon valvuloplasty for pulmonic
stenosis, described in 1982 [1], is a procedure of choice for both adolescent
and adult patients (class I recommendation according to the ACC/AHA
guidelines [2]). There are several reports of patients being treated by
a percutaneous technique, either staged or combined, with no clear
agreement as to which procedure should be performed first [3-4].
Percutaneous balloon valvuloplasty for calcific aortic stenosis might be
considered as a palliative treatment for patients eligible for neither
a surgical approach nor transcatheter aortic valve implantation (TAVI) [2].
There is a report of a combined percutaneous ASD closure and double
balloon valvotomies for mitral and aortic stenosis in a patient with
Lutembacher’s syndrome [5].
Case report
Patient 1
A 63-year-old woman underwent a transthoracic and transoesophageal
echocardiogram due to dyspnoea on exertion (NYHA class II). She was
diagnosed with a large secundum type atrial septal defect (19 mm in
diameter, Figure 1) with left-to-right shunt and pulmonic stenosis (maximal
pressure gradient 49 mmHg). The patient was referred for percutaneous
closure of the ASD and pulmonic balloon valvuloplasty.
Coronary angiography with normal findings was performed via the right
femoral artery. Right heart catheterization was performed via the right
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Copyright © 2010 Termedia & Banachfemoral vein. The left-to-right shunt ratio of
pulmonary blood flow (Qp) to systemic blood flow
(Qs) was assessed to be 1.45 : 1. The peak-to-peak
pressure gradient across the pulmonary valve was
35 mmHg.
First, the ASD was closed using a 21 mm Figulla
Occluder device (Occlutech GmbH, Jena, Germany)
under transoesophageal echocardiographic guidance
(Figure 2). The peak-to-peak pressure gradient across
the valve was measured again and showed 
33 mmHg. Therefore, pulmonary balloon valvulo  -
plasty was performed with a NuCLEUSTM 25 × 30 mm
percutaneous transluminal valvuloplasty catheter
(NuMED, Inc., Hopkinton, NY, Figure 3). The resulting
peak-to-peak pressure gradient was 10 mmHg.
The patient was started on dual antiplatelet
therapy (aspirin 100 mg daily and clopidogrel 75 mg
daily for 6 months). Follow-up echocardiogram 
2 months after the procedure showed no residual
shunt and a maximal pressure gradient across the
pulmonary valve of 38 mmHg and the patient
reported an improvement in the functional class
(NYHA I). Six months after the procedure, the
maximal pressure gradient declined to 25 mmHg
and a recent one-year follow-up showed a further
decline to 16 mm Hg as well as a new dilatation of
the pulmonary artery to a diameter of 50 mm.
Patient 2
A 78-year-old woman was admitted to the
hospital due to heart failure symptoms (dyspnoea,
fatigue, peripheral oedema). Shortly after
admission, respiratory distress occurred due to
pulmonary oedema and the patient had to be
artificially ventilated. Transoesophageal echo  -
cardiogram showed a severe calcific aortic stenosis
with 102 mmHg maximal and 56 mmHg mean
pressure gradient and a large secundum type 
ASD (17 mm in diameter) with left-to-right 
shunt (Figure 4). She was referred for combined
percutaneous aortic balloon valvuloplasty and ASD
closure.
Right heart catheterization was performed via
the right jugular vein. Temporary pacing was
introduced into the right ventricle via the right
Figure 3. Balloon valvuloplasty of pulmonary valvular
stenosis following ASD closure 
Figure  1. Transoesophageal echocardiogram of
a secundum type ASD with a Multipurpose catheter
(Cordis, Miami Lakes, FL) crossing the defect from
right to left atrium
Figure 2. Transoesophageal echocardiogram after
ASD closure 
Figure  4.  Transoesophageal echocardiogram of
a secundum type ASD
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catheterization were performed via the right
femoral artery. No significant coronary stenosis was
found and the left-to-right shunt ratio of Qp to Qs
was 1.5 : 1. Peak-to-peak pressure gradient across
the aortic valve was 50 mmHg. Aortic balloon
valvuloplasty with a NuCLEUSTM 22 × 40 mm
percutaneous transluminal valvuloplasty catheter
(NuMED, Inc., Hopkinton, NY) was accomplished.
The resulting peak-to-peak pressure gradient 
was 10 mmHg. Next, under transoesophageal
echocardiographic guidance, sizing of the ASD using
a 17 mm balloon while measuring the pulmonary
artery (PA) and pulmonary capillary wedge (PCW)
pressures was achieved (Figures 5, 6). After ruling
out elevation in PA pressures during the sizing
balloon inflation, the ASD was successfully closed
with an 18 mm Figulla Occluder device (Occlutech
GmbH, Jena, Germany, Figures 7, 8).
The patient was started on a dual antiplatelet
therapy (aspirin 100 mg daily and clopidogrel 75 mg
daily for 2 months). Shortly after the procedure the
heart failure symptoms subsided. 
The patient died 18 months later of a sudden
cardiac death. The autopsy showed a completely
endothelised Figulla occluder device with no
residual shunt (Figures 9, 10).
Discussion
In adult patients, combined occurrence of
secundum type ASD and pulmonic stenosis is an
uncommon condition. When isolated, both
conditions can be treated percutaneously. Several
reports describing a transcatheter approach for the
treatment of combined secundum type ASD and
pulmonic stenosis vary in answering the question
which defect should be treated first and whether
the procedures should be staged or combined [3-4].
Treating the ASD first should eliminate the left-
to-right shunt and thus also the right ventricle
volume overload and possibly lower the pressure
gradient across the pulmonic valve, enabling one
to reassess the pulmonic stenosis severity. On the
other hand, addressing the pulmonic stenosis first
lowers the peri-procedural risk of ASD occluder
device dislodgement.
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Figure 5. Pulmonary artery pressure measurement
before ASD occlusion 
Figure 6. Pulmonary artery pressure measurement
immediately after ASD occlusion
Figure 7. ASD closure
Figure 8. Transoesophageal echocardiogram after
ASD closure Arch Med Sci 6, December / 2010 979
ASD occlusion and BAV or BPV
With the pulmonic valve peak-to-peak pressure
gradient being only 5 mmHg above the cut-off value
for interventional treatment of pulmonic stenosis
in symptomatic patients (30 mmHg), we decided
to correct the ASD first. The Qp/Qs ratio (1.45 : 1)
was slightly below the 1.5 : 1 value. The ASD itself,
however, was large (19 mm in diameter) and we
expected the left-to-right shunt ratio to be
diminished by the elevated pressures in the right-
sided chambers. Treating the ASD first allowed us
to reassess the pulmonic stenosis, with the peak-
to-peak pressure gradient remaining above the 
30 mmHg threshold, and thus we decided to
proceed with the pulmonic balloon valvuloplasty.
Our patient with pulmonary valvular stenosis
and ASD was older than patients in previously
published reports. She remained asymptomatic up
to the age of 63 years probably due to only
borderline Qp/Qs ratio and only mildly elevated
pulmonary valve pressure gradient. The late
pulmonary artery dilatation in our patient
demonstrates a need for a thorough follow-up
examination.
The percutaneous treatment of ASD and calcific
aortic stenosis has not been previously reported. At
present, with TAVI being an alternative form of
treatment of patients with calcific aortic stenosis
not eligible for surgical valve replacement, aortic
balloon valvuloplasty is being used in fewer cases
or has been abandoned completely [6]. The reasons
for it falling out of favour are mainly a high rate of
restenosis and a small haemodynamic effect.
However, in everyday clinical practice in the setting
of an expanding elderly population there are
patients who could benefit from this procedure [7].
We encountered an older, high-risk patient with
severe comorbidities and in critical condition, who
was eligible for neither surgical treatment, nor TAVI.
Therefore, we decided to perform an aortic balloon
valvuloplasty as a palliative treatment combined
with ASD closure of a large defect with significant
left-to-right shunt. Before the actual occlusion of
the ASD we carefully monitored the PA and PCW
pressure during balloon occlusion of the defect, in
case the elimination of the shunt worsened the
situation in the pulmonary bed.
Our case reports show that secundum type ASD
combined with pulmonic or aortic valve stenosis
can be treated by a one-stage percutaneous
procedure. In the case of ASD and pulmonic
stenosis, there is no clear agreement as to which
defect should be treated first. Before the ASD
closure in a patient with aortic stenosis, a careful
haemodynamic assessment is essential.
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